Neurocrine posts $1.1 billion quarter, raises INGREZZA sales guidance
Neurocrine reported 41% revenue growth for the third quarter of 2026 and lifted full-year INGREZZA guidance while advancing new obesity and Alzheimer's programs.
Neurocrine Biosciences reported third-quarter 2026 financial results on November 2, 2026, with total revenues of $1.1 billion, compared with $795 million in the prior-year period, representing 41% year-over-year growth.1 The company raised its full-year INGREZZA guidance from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion.1
On the pipeline side, Neurocrine announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.1 This follows the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-'2118, a potential first-in-class CRF2 peptide agonist,1 and initial clinical data from both programs will inform development of a novel co-formulated combination therapy, with NBIP-'2118 also to be evaluated independently as a potential standalone obesity therapy.1
The company also announced the initiation of a Phase 2 clinical study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-'567, an investigational M1/M4 (M1-preferring) selective muscarinic agonist being developed as an adjunctive therapy for cognitive impairment in Alzheimer's disease.1
Looking ahead, CEO Kyle Gano said the company sees meaningful opportunities for continued growth across INGREZZA, CRENESSITY and VYKAT XR into 2027, alongside clinical milestones including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia.1 Neurocrine also said Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the Company's executive management team as Chief Medical Officer.1
On cash, at September 30, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $790 million.1 Neurocrine will host an R&D Day in New York on December 15, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.